此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

The ABODE Study for Patients Undergoing Neoadjuvant Chemotherapy (ABODE NAC)

2026年11月15日 更新者:University Health Network, Toronto

At-home Breast Oncology Care Delivered With E-health Solutions - The ABODE Study for Patients Undergoing Neoadjuvant Chemotherapy

Over 12,000 women in Ontario will be diagnosed with BC this year. The COVID-19 pandemic changed the healthcare system, making it important to have high-quality virtual (online) care. Mobile health, which means getting health services on your phone, has become a common part of healthcare.

A previously developed app will be used in this study to improve the virtual care experience for BC patients that will be undergoing neoadjuvant chemotherapy. With this app, patients can:

  • Get personalized resources that can help them navigate through the stages of their treatment.
  • Access vetted information about their cancer & treatment from a health library.
  • Receive surveys about their health and well-being.
  • Get mental and social support from an e-coach, who are volunteers trained to help and support patients. The e-coaches will provide information, listen to how participants are feeling, and help participants find information they might need.
  • Connect with a physiotherapist to discuss healthy living and wellness.

Participants will be randomly put into one of two groups: one group will use the app, while the other will continue to get usual care without the app. Participants will have access to the app for 12 months. They will be asked about their experience, how they are feeling, and their health status at several timepoints.

At the end of the study, the two groups will be compared to see how active and engaged participants are in their treatment and see how this changes over 12 months. The study team will also examine how participants are feeling emotionally and their overall quality of life. Health service utilization data and chart review will be used to examine how patients used health services over the course of their treatment. Qualitative interviews will be conducted for some patients about their treatment and experience on the app, using photos that they submit throughout the study.

研究概览

研究类型

介入性

注册 (估计的)

200

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Ontario
      • Toronto、Ontario、加拿大、M5G2M9
        • University Health Network
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Females (assigned female at birth)*
  • Diagnosed with primary invasive BC and receiving curative intent treatment
  • Must have neoadjuvant chemotherapy as their first step in treatment
  • Receiving systemic therapy at UHN
  • Age≥18
  • Access to an electronic device with connection to the internet
  • A valid email address
  • Can communicate in English

Exclusion Criteria:

  • Males (assigned male at birth), as BC surgical treatment options and experiences are different
  • Diagnosed with non-operable breast cancer
  • Stage 4/metastatic (whether determined at diagnosis or during surgery)
  • Those with hearing or visual challenges
  • Should not be enrolled in any other UHN study using an e-Health application

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
无干预:Control

Standard care

实验性的:Intervention (App)

App + standard care

The app is a customized version of an eHealth platform that is already in use in other disease sites at UHN. The app has been approved by UHN as a secure communication method. We have customized the app to function within breast cancer care pathways.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Patient Activation Measure 13 (PAM-13)
大体时间:Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

A 13-item scale measuring self-reported knowledge, skills and confidence for self-management of one's health and healthcare. Items are rated on a 4-point Likert scale (1 = strongly disagree, 2 = disagree, 3 = agree, 4 = strongly agree). Higher scores indicate a greater patient activation.

Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

次要结果测量

结果测量
措施说明
大体时间
Impact of Events Scale - Revised (IES-R)
大体时间:Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

A 22-item scale measuring subjective distress as it relates to a specific event, based on intrusion and avoidance. Items are rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely"). The IES-R yields a total score (ranging from 0 to 88); higher scores mean worse symptoms.

Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
Generalized Anxiety Disorder 7 (GAD-7)
大体时间:Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

A 7-item measure of generalized anxiety disorder based on symptoms. The GAD-7 is scored by adding its seven items (each 0-3), producing a total from 0-21. Higher scores indicate higher anxiety.

Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire: EORTC QLQ-C30
大体时间:Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

A 30-item survey assessing of quality of life in cancer patients. The EORTC Core Questionnaire (QLQ-C30) includes six clearly distinguishable functioning scales that have been thoroughly tested and validated. Raw item averages are transformed into a 0-100 scale, where higher scores indicate better functioning (for function/global scales) or worse symptoms (for symptom scales).

Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire Information Module (EORTC-INFO25)
大体时间:9 months post-baseline

A 25-item survey to measure the amount of medical information received throughout treatment. This scale uses a 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale indicate higher satisfaction with provided treatment information.

9 months post-baseline
European Organisation for Research and Treatment of Cancer - Breast Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR42)
大体时间:Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

A 42-item survey assessing quality of life specifically for breast cancer patients.

The survey includes functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions used 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. A high score for functional scale indicate a high/healthy level of functioning while a high score for single item indicate a high level of symptomatology/problems.

Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
Health Education Impact Questionnaire (heiQ)
大体时间:Baseline 9 months post-baseline

A 40-item scale measuring the intended outcomes of health education and self-management programs. heiQ is a validated, self-reported instrument with 8 domains to comprehensively evaluate patient education program and self-management intervention. Each domain score ranges from 1 to 4; a higher score indicates better outcome.

Baseline 9 months post-baseline
Clinical Evaluation Questionnaire -INS (CEQ-INS)
大体时间:9 months post-baseline

A 19-item scale evaluation of patient's experience of cancer care in terms of their receipt of useful and relevant information about cancer, assistance with service navigation, and support from their care team. CEQ-INS is a self-reported instrument with questions used 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Higher scores correlate with higher patient satisfaction with the information and support provided from their care team.

9 months post-baseline
Health Service Outcomes - Wait Times
大体时间:Until 15 months post-baseline

The length of time from referral to procedure or discharge, as recorded in the Wait Times Information System (TIS), which tracks wait times for surgeries, diagnostic imaging (e.g., MRI, CT), and alternate level of care (ALC) in Ontario hospitals.

Until 15 months post-baseline
Health Service Outcomes - Ambulatory Clinical Activity
大体时间:Until 15 months post-baseline

Ambulatory clinical activity will be collected from the National Ambulatory Care Reporting System (NACRS).

Until 15 months post-baseline
Health Service Outcomes - Discharge Information
大体时间:Until 15 months post-baseline

Discharge information will be collected from the Discharge Abstracting Database (DAD) and used to understand discharge and patient recovery.

Until 15 months post-baseline

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月1日

初级完成 (估计的)

2028年10月1日

研究完成 (估计的)

2028年10月1日

研究注册日期

首次提交

2026年10月28日

首先提交符合 QC 标准的

2026年11月15日

首次发布 (实际的)

2026年11月20日

研究记录更新

最后更新发布 (实际的)

2026年11月20日

上次提交的符合 QC 标准的更新

2026年11月15日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅